Resistance to anti-HCV protease inhibitors

被引：41

作者：

Thompson, Alexander J. ^{[1
,2
]}

Locarnini, Stephen A. ^{[2
]}

Beard, Michael R. ^{[3
]}

机构：

[1] St Vincents Hosp Melbourne, Fitzroy, Vic, Australia

[2] Victorian Infect Dis Reference Lab, Melbourne, Vic, Australia

[3] Inst Med & Vet Sci, Infect Dis Labs, Adelaide, SA 5000, Australia

来源：

CURRENT OPINION IN VIROLOGY | 2011年 / 1卷 / 06期

关键词：

HEPATITIS-C VIRUS; CRYSTAL-STRUCTURE; NONNUCLEOSIDE POLYMERASE; ADAPTER PROTEIN; TELAPREVIR; REPLICATION; COMBINATION; BOCEPREVIR; HELICASE; VARIANTS;

D O I：

10.1016/j.coviro.2011.10.001

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

The era of direct acting antiviral therapy for HCV infection has dawned with the recent approval of the NS3 protease inhibitors telaprevir and boceprevir. The development of DAA therapy is an exciting advance for clinicians and patients, but it will also bring new challenges. For the first time, drug resistance has become an issue to consider in the management of HCV. This brief review summarizes the current literature concerning resistance to the HCV NS3 protease inhibitors, both experimental and clinical, and identifies the key questions facing the field.

引用

页码：599 / 606

页数：8

共 50 条

[1] Second wave anti-HCV protease inhibitors: too little too late?
De Nicola, Stella
Aghemo, Alessio
LIVER INTERNATIONAL, 2014, 34 (07) : E168 - E170
[2] Discovering novel anti-HCV compounds with inhibitory activities toward HCV NS3/4A protease
Yu, Ye
Jing, Jing-feng
Tong, Xian-kun
He, Pei-lan
Li, Yuan-chao
Hu, You-hong
Tang, Wei
Zuo, Jian-ping
ACTA PHARMACOLOGICA SINICA, 2014, 35 (08) : 1074 - 1081
[3] Resistance Mutations Against HCV Protease Inhibitors and Antiviral Drug Design
Shang, Luqing
Lin, Kai
Yin, Zheng
CURRENT PHARMACEUTICAL DESIGN, 2014, 20 (05) : 694 - 703
[4] Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients
Trimoulet, P.
Belzunce, C.
Faure, M.
Wittkop, L.
Reigadas, S.
Dupon, M.
Ragnaud, J-M
Fleury, H.
Neau, D.
HIV MEDICINE, 2011, 12 (08) : 506 - 509
[5] Anti-HCV drugs in the pipeline
Yang, Priscilla L.
Gao, Min
Lin, Kai
Liu, Qingsong
Villareal, Valerie A.
CURRENT OPINION IN VIROLOGY, 2011, 1 (06) : 607 - 616
[6] HCV Genotypes Are Differently Prone to the Development of Resistance to Linear and Macrocyclic Protease Inhibitors
Cento, Valeria
Mirabelli, Carmen
Salpini, Romina
Dimonte, Salvatore
Artese, Anna
Costa, Giosue
Mercurio, Fabio
Svicher, Valentina
Parrotta, Lucia
Bertoli, Ada
Ciotti, Marco
Di Paolo, Daniele
Sarrecchia, Cesare
Andreoni, Massimo
Alcaro, Stefano
Angelico, Mario
Perno, Carlo Federico
Ceccherini-Silberstein, Francesca
PLOS ONE, 2012, 7 (07):
[7] Dynamic change in the NS3 protease domain in HIV/HCV-coinfected patients naive to anti-HCV protease inhibitors
Bagaglio, Sabrina
Messina, Emanuela
Hasson, Hamid
Merli, Marco
Andolina, Andrea
Lazzarin, Adriano
Uberti-Foppa, Caterina
Morsica, Giulia
NEW MICROBIOLOGICA, 2017, 40 (01) : 53 - 55
[8] Pharmacophore feature prediction and molecular docking approach to identify novel anti-HCV protease inhibitors
Venkatesan, Arthi
Rambabu, Majji
Jayanthi, Sivaraman
Dass, J. Febin Prabhu
JOURNAL OF CELLULAR BIOCHEMISTRY, 2018, 119 (01) : 960 - 966
[9] A UPLC-MS/MS method for the simultaneous plasma quantification of all isomeric forms of the new anti-HCV protease inhibitors boceprevir and telaprevir
D'Avolio, Antonio
De Nicolo, Amedeo
Agnesod, Danilo
Simiele, Marco
Abdi, Adnan Mohamed
Penchala, Sujan Dilly
Boglione, Lucio
Cariti, Giuseppe
Di Perri, Giovanni
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2013, 78-79 : 217 - 223
[10] Development of novel anti-HCV therapies: HCV protease, helicase, and polymerase as therapeutic targets
Hong, Z
Standring, DN
Baroudy, B
Lau, JYN
ACTA GASTRO-ENTEROLOGICA BELGICA, 2000, 63 (02): : 210 - 212

← 1 2 3 4 5 →